MaaT Pharma H1 operating loss widens 29% to EUR 19 million; revenue drops 55% to EUR 1.08 million
Bitget2026/09/29 16:03- MaaT Pharma posted H1 2026 revenue down 56% to EUR 1.08 million, while net loss widened 22% to EUR 18.33 million.
- R&D expenses climbed 30% to EUR 19.2 million, while operating loss widened 29% to EUR 19 million.
- Cash and cash equivalents fell to EUR 17.1 million at June 30, 2026, from EUR 24.9 million at Dec. 31, 2025.
- Management said cash-preservation measures extend its cash runway to December 2026, and it is exploring financing and partnerships.
- CHMP maintained its negative opinion on MaaT013’s conditional marketing application; MaaT Pharma proposed the PHOENIX Phase 3 trial.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BMO lowers Novo Nordisk's target price to $40
Microsoft (MSFT.US) Azure reportedly seeks a 20% cost reduction: intensifying AI costs and talent competition, with simultaneous restructuring of cloud leadership
According to reports, Microsoft (MSFT.US) Azure President Girish Bablani has asked senior leaders in his department to look for ways to reduce costs by at least 20%.
Oil and gas equipment manufacturer VME Companies (VME.US) sets IPO price at $4-$5 per share, plans to raise $18 million
VME Companies, a supplier of offshore oil and gas facility process modules and separation equipment, announced the terms of its IPO on Tuesday.
Wall Street veteran who warned of previous financial crises sounds the bubble alarm: US stock valuations, leverage, and positions are at their most extreme levels in 40 years of industry experience.
David Rosenberg has warned that this is the most tense market in his 40-year career.
Crypto prices
More
